Meridian Bioscience, Inc.
Meridian Bioscience, Inc. Fundamental Analysis
Meridian Bioscience, Inc. (VIVO) shows weak financial fundamentals with a PE ratio of 35.21, profit margin of 12.75%, and ROE of 12.19%. The company generates $0.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 66.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze VIVO's fundamental strength across five key dimensions:
Efficiency Score
WeakVIVO struggles to generate sufficient returns from assets.
Valuation Score
ModerateVIVO shows balanced valuation metrics.
Growth Score
ModerateVIVO shows steady but slowing expansion.
Financial Health Score
ExcellentVIVO maintains a strong and stable balance sheet.
Profitability Score
WeakVIVO struggles to sustain strong margins.
Key Financial Metrics
Is VIVO Expensive or Cheap?
P/E Ratio
VIVO trades at 35.21 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, VIVO's PEG of 0.35 indicates potential undervaluation.
Price to Book
The market values Meridian Bioscience, Inc. at 4.06 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 21.37 times EBITDA. This signals the market has high growth expectations.
How Well Does VIVO Make Money?
Net Profit Margin
For every $100 in sales, Meridian Bioscience, Inc. keeps $12.75 as profit after all expenses.
Operating Margin
Core operations generate 16.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $12.19 in profit for every $100 of shareholder equity.
ROA
Meridian Bioscience, Inc. generates $9.17 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Meridian Bioscience, Inc. produces operating cash flow of $82.02M, showing steady but balanced cash generation.
Free Cash Flow
Meridian Bioscience, Inc. generates strong free cash flow of $73.44M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.68 in free cash annually.
FCF Yield
VIVO converts 4.95% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
35.21
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.35
vs 25 benchmark
P/B Ratio
Price to book value ratio
4.06
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.47
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.08
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.12
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How VIVO Stacks Against Its Sector Peers
| Metric | VIVO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 35.21 | 29.43 | Worse (Expensive) |
| ROE | 12.19% | 800.00% | Weak |
| Net Margin | 12.75% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.08 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 3.63 | 4.64 | Strong Liquidity |
| ROA | 9.17% | -17936.00% (disorted) | Weak |
VIVO outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Meridian Bioscience, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation